BROWNSTEIN HYATT FARBER SCHRECK, LLP

Lobbying for ABBVIE · Biopharmaceutical company

Amended

The filer submitted a later report covering this same period, so the amounts here have been replaced. Site totals count only the latest version. See the current filing, posted Apr 18, 2025.

Filing 1st Quarter - Report

Reporting period

1st Quarter 2025

Jan 1 - Mar 31 · Posted Apr 18, 2025

Income

$80,000.00

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 1

SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Lobbying activity 1

Health Issues

Issues related to patient access, pharmaceutical manufacturing, Patent reform and drug pricing both domestic and international Issues related to Medicare drug pricing and reimbursement HELP Copays Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.